Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RenovoRx, Inc.RNXT · Entity 6797 | Director · Chief Executive Officer | April 03, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RenovoRx, Inc.
Report date April 03, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.98 | Direct | 946,107 |
Reported balance
After 2026-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-03 · Grant · Acquired 946,107 · Balance 946,107 F1: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2026 Filed Apr 8, 2026 00:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 946,107 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-26-015594 · ownership.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,107 Underlying: Common Stock · 946,107 shares Expires not disclosed F1 · derivative.exercise_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. F1 · derivative.expiration_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 946,107 shares of the Issuer's common stock (111,621 shares of which are underlying incentive stock options and 834,486 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. Read SEC document |
| March 20, 2026 Filed Mar 25, 2026 01:16 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseWarrants · Derivative | 12,150 | Not disclosed Strike: $1.93 | Not disclosed |
DisclosureSEC source: 0001493152-26-012482 · ownership.xml · derivative · entry 3 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Bagai Family Trust Disclosed balance after: 12,150 Underlying: Common Stock · 12,150 shares Expires not disclosed F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000. F2 · derivative.exercise_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report. F2 · derivative.expiration_date: The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report. Read SEC document |
| March 20, 2026 Filed Mar 25, 2026 01:16 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 24,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-012482 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · The Bagai Family Trust Disclosed balance after: 313,357 F1 · price: The securities were purchased in a private placement on March 20, 2026 for an aggregate of $25,000. F3 · balance_after: 289,057 shares of common stock are held of record by The Bagai Family Trust and were previously reported as "directly" beneficially held by the Reporting Person. Read SEC document |
| December 18, 2025 Filed Dec 22, 2025 12:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 5,000 | $0.90 | $4,506.50 |
DisclosureSEC source: 0001493152-25-028650 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,040 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 12:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 5,000 | $0.85 | $4,262.00 |
DisclosureSEC source: 0001493152-25-028439 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,040 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 10:10 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 5,000 | $0.91 | $4,549.00 |
DisclosureSEC source: 0001641172-25-025459 · ownership.xml · nonDerivative · entry 2 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,040 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 10:10 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 5,000 | $0.95 | $4,747.50 |
DisclosureSEC source: 0001641172-25-025459 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,040 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:45 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 102,498 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001641172-25-017832 · ownership.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,498 Underlying: Common Stock · 102,498 shares Expires not disclosed F1 · shares: Represents an award of 21,072 incentive stock options and 81,426 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. F2 · derivative.exercise_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. F2 · derivative.expiration_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. F1 · derivative.underlying_shares: Represents an award of 21,072 incentive stock options and 81,426 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 10:08 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 7,500 | $0.91 | $6,821.25 |
DisclosureSEC source: 0001641172-25-004955 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,040 F1 · shares: Reflects open market purchases of the Issuer's securities. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:18 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 409,992 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001641172-25-005107 · ownership.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,992 Underlying: Common Stock · 409,992 shares Expires not disclosed F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 409,992 shares of the Issuer's common stock (187,812 shares of which are underlying incentive stock options and 222,180 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035. F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 409,992 shares of the Issuer's common stock (187,812 shares of which are underlying incentive stock options and 222,180 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 10:02 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 10,000 | $0.83 | $8,300.00 |
DisclosureSEC source: 0001641172-25-003504 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,540 F1 · shares: Reflects open market purchases of the Issuer's securities. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82795 to $0.829, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 15:30 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 10,000 | $0.83 | $8,300.00 |
DisclosureSEC source: 0001641172-25-003158 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,540 F1 · shares: Reflects open market purchases of the Issuer's securities. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.816 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 23:57 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseWarrants · Derivative | 40,983 | Not disclosed Strike: $1.22 | Not disclosed |
DisclosureSEC source: 0001493152-24-004368 · ownership.xml · derivative · entry 2 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,983 Underlying: Common Stock · 40,983 shares Expires not disclosed F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 23:57 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 40,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-004368 · ownership.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,540 F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:50 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 250,263 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001493152-24-003521 · ownership.xml · derivative · entry 2 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,263 Underlying: Common Stock · 250,263 shares Expires not disclosed F2 · derivative.exercise_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 250,263 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034. F2 · derivative.expiration_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 250,263 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:50 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 66,973 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001493152-24-003521 · ownership.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,973 Underlying: Common Stock · 66,973 shares Expires not disclosed F1 · derivative.exercise_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 66,973 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, expires on January 19, 2034. F1 · derivative.expiration_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 66,973 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, expires on January 19, 2034. Read SEC document |
| March 15, 2023 Filed Mar 29, 2023 20:55 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001493152-23-009494 · ownership.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-03-15 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 1, 2023. Read SEC document |
| May 19, 2022 Filed May 23, 2022 10:09 UTC | RenovoRx, Inc. RNXT · Entity 6797 | PurchaseCommon Stock | 5,500 | $2.05 | $11,275.00 |
DisclosureSEC source: 0001209191-22-031236 · doc4.xml · nonDerivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,557 F1 · balance_after: Includes 246,057 shares previously reported on a Form 3 filed on August 25, 2021 as a fully vested stock option exercisable at $0.15 per share. The option was exercised in full prior to the Issuer's initial public offering. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:12 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantEmployee Stock Option (right to buy) · Derivative | 48,313 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-018448 · doc4.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,313 Underlying: Common Stock · 48,313 shares Expires 2032-03-10 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on September 26, 2021. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:07 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantEmployee Stock Option (right to buy) · Derivative | 117,866 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001209191-21-059159 · doc4.xml · derivative · entry 1 Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,866 Underlying: Common Stock · 117,866 shares Expires 2031-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on September 26, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.